NDUFAF6: A Potential Drug Target and Biomarker (G137682)

Target Name: NDUFAF6

NCBI ID: G137682

NDUFAF6

Other Name(s): NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 isoform X1 | NDUFAF6 variant 1 | NDUFAF6 variant X1 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (isoform 7) | NDUFAF6 variant 20 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 1 | NDUFAF6 variant 4 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 5 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 4 | NDUFAF6 variant 12 | FRTS5 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 11 | NDUFAF6 variant 5 | NDUFAF6 variant 10 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 20 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (isoform 6) | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (isoform 2) | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant X1 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 3 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 | C8orf38 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 10 | NDUFAF6 variant 3 | Putative phytoene synthase | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant 12 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 isoform 6 | UPF0551 protein C8orf38, mitochondrial | NDUFAF6 variant 11 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (isoform 1) | NDUF6_HUMAN | putative phytoene synthase | NDUFAF6 variant X3 | NADH:ubiquinone oxidoreductase complex assembly factor 6 | MC1DN17 | NADH:ubiquinone oxidoreductase complex assembly factor 6, transcript variant X3

NDUFAF6: A Potential Drug Target and Biomarker

NADH (nicotinamide adenine dinucleotide) is a crucial molecule in cellular metabolism that plays a vital role in the production of energy. NAD+ is a central coenzyme for many cellular processes, including the production of ATP, the metabolism of fatty acids, and the detoxification of harmful substances. NADH dehydrogenase (NDUFAF6) is a protein that belongs to the NADH-dependent superfamily 6, which is involved in the production of NAD+ from NADH. NDUFAF6 is a protein that is expressed in most tissues and cells and is involved in the energy metabolism of the cell.

The NDUFAF6 protein is composed of several subunits that are arranged in a specific order to carry out its functions. The subunits of NDUFAF6 include the alpha subunit, beta subunit, gamma subunit, delta subunit, and epsilon subunit. The alpha subunit is the N-terminus of the protein and is responsible for the binding of NAD+ to the protein. The beta subunit is the catalytic subunit and is responsible for the NADH dehydrogenase reaction. The gamma subunit is the Co2-transport subunit and is responsible for the transport of CO2 from the cytosol to the mitochondria. The delta subunit is the Fe-subunit and is responsible for the Fe3+-dependent catalytic activity of the protein. The epsilon subunit is the GTP-binding subunit and is responsible for the binding of GTP to the protein.

NDUFAF6 is a protein that is expressed in most tissues and cells and is involved in the energy metabolism of the cell. It is a key enzyme in the production of NAD+, which is a central coenzyme for many cellular processes, including the production of ATP, the metabolism of fatty acids, and the detoxification of harmful substances. NDUFAF6 is also involved in the detoxification of NADH, which is a toxic compound that can be produced by the metabolism of fatty acids.

The potential drug target for NDUFAF6 is the production of NAD+ and its role in energy metabolism. Drugs that can increase the production of NAD+ and decrease the production of NADH may be useful for treating various diseases, such as cancer, heart disease, and neurodegenerative disorders. Some studies have shown that NAD+ levels are decreased in the brains of individuals with neurodegenerative disorders, and that supplementation with NAD+ has been shown to improve cognitive function in these individuals.

In addition to its role in energy metabolism, NDUFAF6 is also involved in the regulation of cellular processes. Studies have shown that NDUFAF6 is involved in the regulation of cell growth, differentiation, and apoptosis. NDUFAF6 has also been shown to be involved in the regulation of inflammation and immune response.

TheNDUFAF6 gene has been studied extensively and has been shown to be involved in many cellular processes. Several studies have shown that NDUFAF6 is involved in the production of NAD+ from NADH. These studies have also shown that NDUFAF6 is involved in the regulation of cell growth, differentiation, and apoptosis. In addition, studies have shown that NDUFAF6 is involved in the regulation of inflammation and immune response.

In conclusion, NDUFAF6 is a protein that is involved in the production of NAD+ and its role in energy metabolism. Studies have shown that NDUFAF6 is also involved in the regulation of cell growth, differentiation, and apoptosis. Additionally, NDUFAF6 is involved in the regulation of inflammation and immune response. Given its involvement in these processes, NDUFAF6 may be a potential drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand the role of NDUFAF6 in

Protein Name: NADH:ubiquinone Oxidoreductase Complex Assembly Factor 6

Functions: Involved in the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I) at early stages. May play a role in the biogenesis of complex I subunit MT-ND1

The "NDUFAF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFAF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets